ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosisXavier Montalbán, Frauke Zipp, Ralf Gold et al.|Multiple Sclerosis Journal|2018Cited by 706
Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumabMartin Gunnarsson, Jan Lycke, Clas Malmeström et al.|Annals of Neurology|2010Cited by 347
Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumabPer Soelberg Sørensen, Tomas Olsson, Antonio Bertolotto et al.|Multiple Sclerosis Journal|2012Cited by 236
<scp>ECTRIMS</scp>/<scp>EAN</scp> guideline on the pharmacological treatment of people with multiple sclerosisXavier Montalbán, Frauke Zipp, Ralf Gold et al.|European Journal of Neurology|2018Cited by 222
Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromesEster Cantó, Manuel Comabella, Mar Tintoré et al.|Brain|2015Cited by 191